help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simpson, J. F.
Right arrow Articles by Page, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpson, J. F.
Right arrow Articles by Page, D. L.

American Journal of Pathology, Vol 141, 285-289, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Altered expression of a structural protein (fodrin) within epithelial proliferative disease of the breast

JF Simpson and DL Page
Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee.

Although certain histopathologic patterns of epithelial proliferative breast disease are well established as indicating an increased relative risk for the subsequent development of mammary carcinoma, the biologic characterization of these changes is not known. One evident histologic characteristic of epithelial hyperplasia is the partial or complete loss of normal cellular polarity. Nonerythroid spectrin (fodrin) is a structural protein whose function is related to maintenance of cellular polarity. By immunohistochemical analysis, normal breast luminal epithelia contain fodrin confined to a characteristic basolateral distribution. Proliferative breast disease of the common type partially loses this polarized distribution of fodrin; fodrin immunoreactivity is not limited to a basolateral location but is present around the cell membrane and is inconsistently present at luminal interfaces. Whether this change in distribution of fodrin is a permissive event in the development of proliferative disease or merely an associated finding is not known.


This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
C. J. FABIAN and B. F. KIMLER
Beyond Tamoxifen: New Endpoints for Breast Cancer Chemoprevention, New Drugs for Breast Cancer Prevention
Ann. N.Y. Acad. Sci., December 1, 2001; 952(1): 44 - 59.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Society for Investigative Pathology.